Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup …
Introduction Non-small-cell lung cancer (NSCLC) is the leading cause of cancer death in
China. Four epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors …
China. Four epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors …
[HTML][HTML] Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations …
YL Wu, CR Xu, CP Hu, J Feng, S Lu… - OncoTargets and …, 2018 - ncbi.nlm.nih.gov
Materials and methods Previously untreated patients with EGFR mutation-positive stage
IIIB/IV lung adenocarcinoma were randomized 2: 1 to receive afatinib or≤ 6 cycles of …
IIIB/IV lung adenocarcinoma were randomized 2: 1 to receive afatinib or≤ 6 cycles of …
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup …
YL Wu, CR Xu, CP Hu, J Feng, S Lu… - OncoTargets & …, 2018 - search.ebscohost.com
Introduction: Non-small-cell lung cancer (NSCLC) is the leading cause of cancer death in
China. Four epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors …
China. Four epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors …
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup …
YL Wu, CR Xu, CP Hu, J Feng, S Lu… - Oncotargets and …, 2018 - europepmc.org
Materials and methods Previously untreated patients with EGFR mutation-positive stage
IIIB/IV lung adenocarcinoma were randomized 2: 1 to receive afatinib or≤ 6 cycles of …
IIIB/IV lung adenocarcinoma were randomized 2: 1 to receive afatinib or≤ 6 cycles of …
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFRmutations: subgroup …
W Yi-Long, X Chong-Rui, H Cheng-Ping… - OncoTargets and …, 2018 - search.proquest.com
Introduction: Non-small-cell lung cancer (NSCLC) is the leading cause of cancer death in
China. Four epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors …
China. Four epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors …
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup …
YL Wu, CR Xu, CP Hu, J Feng, S Lu… - OncoTargets and …, 2018 - dovepress.com
Materials and methods: Previously untreated patients with EGFR mutation-positive stage
IIIB/IV lung adenocarcinoma were randomized 2: 1 to receive afatinib or≤ 6 cycles of …
IIIB/IV lung adenocarcinoma were randomized 2: 1 to receive afatinib or≤ 6 cycles of …
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup …
YL Wu, CR Xu, CP Hu, J Feng, S Lu, Y Huang… - OncoTargets and …, 2018 - go.gale.com
Introduction: Non-small-cell lung cancer (NSCLC) is the leading cause of cancer death in
China. Four epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors …
China. Four epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors …
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup …
YL Wu, CR Xu, CP Hu, J Feng, S Lu… - OncoTargets and …, 2018 - pubmed.ncbi.nlm.nih.gov
Introduction Non-small-cell lung cancer (NSCLC) is the leading cause of cancer death in
China. Four epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors …
China. Four epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors …